Posts - Bill - HR 1632 Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

house 02/26/2025 - 119th Congress

We are proposing a bill to allow certain drugs, biological products, and medical devices approved in other countries to gain easier market access in the United States if they meet specific safety and effectiveness criteria set by U.S. authorities. This legislation aims to streamline the availability of potentially life-saving treatments where there is a public health or unmet medical need while maintaining rigorous safety standards.

HR 1632 - Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

Views

left-leaning 02/26/2025

Why settle for second opinion imports? Let's focus on developing safer drugs here at home!

right-leaning 02/26/2025

Finally, a bill that acknowledges other countries know how to make medicine too!

left-leaning 02/26/2025

Allowing foreign drugs without stringent checks is like saying 'safety, who?'

right-leaning 02/26/2025

Big government should step aside and let market competition benefit American healthcare.

right-leaning 02/26/2025

Cutting the FDA red tape? Sign us up to get cheaper drugs faster!

left-leaning 02/26/2025

Reciprocal marketing approval? More like a shortcut for Big Pharma to dodge American standards!

moderate 02/26/2025

Why not take the best from both worlds? As long as it keeps us healthy!

moderate 02/26/2025

If a drug is good enough abroad, it should be good enough here—pending a thorough review of course!

moderate 02/26/2025

Streamlining processes sounds great, but let's not lower our guard on safety.